May 16, 2022 — Bright Green Corporation (“Bright Green”), one of the very few companies selected by the U.S. government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export, today announced that it expects that trading of its common stock on Nasdaq will commence on May 17, 2022 under the symbol “BGXX.”
Bright Green has filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) relating to the proposed direct listing of its common stock, which was declared effective by the SEC on May 13, 2022 (the “Registration Statement”).
When available, the prospectus related to the Registration Statement will be available on the SEC’s website at https://www.sec.gov and a copy of the prospectus may be obtained from Bright Green’s Investor Relations department via email at BrightGreenIR@edelman.com.
About Bright Green
Bright Green is one of the very few companies selected by the US government to grow, manufacture, and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. Our conditional approval based on already agreed terms from the U.S. Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.brightgreen.us.
